These novel transferrin-bearing zein-based hybrid lipid nanoparticles therefore hold promising prospects as a novel approach for prostate cancer treatment and warrant further investigation to assess the combination of docetaxel and plasmid DNA for cancer therapy. Here, TF is linked to Familial prostate cancer.